Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dexamethasone sodium phosphate + bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine** is a multi-component pharmaceutical kit marketed as **Mardex 25 Kit** by **Asclemed USA**. The kit combines dexamethasone sodium phosphate, a glucocorticoid receptor agonist corticosteroid that suppresses inflammatory signaling, with bupivacaine hydrochloride, an amide local anesthetic that blocks voltage-gated sodium channels to inhibit nerve impulse conduction and provide local or regional anesthesia and analgesia; isopropyl alcohol and povidone-iodine are included as topical antiseptic skin-preparation components for the procedure. Public labeling describes the kit as intended for anesthesia and analgesia-related procedural use and shows a package containing bupivacaine HCl 0.25% single-dose vial, dexamethasone sodium phosphate injection 10 mg/mL, povidone-iodine swabsticks, and 70% isopropyl alcohol prep pads. The product is listed in DailyMed as an unapproved drug product whose labeling has not been approved by the FDA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone sodium phosphate + bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine.